Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion ($2.8B upfront), the largest psychedelic acquisition to date, centered on a 5-MeO-DMT nasal spray for treatment-resistant depression now in Phase III.
Source: Axios →The FDA published its final guidance, 'Psychedelic Drugs: Considerations for Clinical Investigations,' giving developers the most detailed regulatory roadmap the field has received.
Source: Federal Register →HHS and the VA signed a cooperation agreement to expand psychedelic research, clinical-trial participation, and clinician training for veterans' mental health.
Source: Military Times →Compass Pathways reported durable six-month Phase 3 results for its COMP360 psilocybin therapy in treatment-resistant depression, with an NDA submission planned for Q4 2026.
Source: Psychiatry Advisor →Otsuka Pharmaceutical acquired Transcend Therapeutics for $1.2 billion, extending Big Pharma's move into psychedelic-based mental health treatments.
Source: CNBC →The VA launched an MDMA-assisted therapy trial for PTSD and alcohol use disorder; the department now runs 19 active psychedelic trials backed by more than $23 million in external funding.
Source: The American Legion →Executive Order 14401 directed $50 million through ARPA-H to match state psychedelic-research investment, FDA priority review vouchers, and a Right-to-Try pathway for ibogaine.
Source: The White House →The FDA issued its first psychedelic priority review vouchers—to Compass and Usona for psilocybin and Otsuka for methylone—and cleared DemeRx's noribogaine for the first U.S. trial of an ibogaine derivative.
Source: STAT →Compass Pathways' COMP360 psilocybin met the primary endpoint in its second pivotal Phase 3 trial for treatment-resistant depression.
Source: Compass Pathways →Gilgamesh Pharma raised a $60 million Series A, the first financing for the company spun out after AbbVie acquired its lead psychedelic candidate.
Source: Psychedelic Alpha →Psychedelic sector financings reached their highest level since 2021, led by Definium Therapeutics ($259M), Helus Pharma ($175M), and AtaiBeckley ($149.5M).
Source: Psychedelic Alpha →Compass Pathways' COMP360 psilocybin met the primary endpoint in its first pivotal Phase 3 trial—the first classic psychedelic to report Phase 3 efficacy data.
Source: Compass Pathways →Texas allocated $50 million for ibogaine clinical research—the state commitment that EO 14401's ARPA-H matching funds are designed to pair with.
Source: Frier Levitt →AbbVie acquired Gilgamesh Pharmaceuticals' lead next-generation psychedelic compound for $1.2 billion.
Source: CNBC →Lykos Therapeutics raised a $50 million Series B as private financing returned to the psychedelic sector.
Source: Psychedelic Alpha →This content is market information provided for general and investor-relations purposes only, and is not investment or medical advice.